Charles River director granted 1,438-share stock award

Charles River Laboratories International director Paul W. Graves received a stock award as part of his compensation.

Rhea-AI Filing Summary

Charles River Laboratories International director Paul W. Graves received a stock award as part of his compensation. On the reported date, he acquired 1,438 shares of common stock at a value of $177.62 per share through a grant, not an open-market purchase. Following this award, his directly held stake increased to 2,384 shares. The underlying restricted stock units will vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders.

Insider Trade Summary

Grant/Award: 1,438 shares

Grant/Award 1 txn

Insider Graves Paul W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,438	$177.62	$255K

Holdings After Transaction: Common Stock — 2,384 shares (Direct)

Footnotes (1)

1. F1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

Key Figures

Stock award size: 1,438 shares Grant value per share: $177.62 per share Holdings after transaction: 2,384 shares +1 more

4 metrics

Stock award size 1,438 shares Common stock grant on May 8, 2026

Grant value per share $177.62 per share Valuation used for the 1,438-share award

Holdings after transaction 2,384 shares Total direct ownership following the grant

RSU vesting date May 8, 2027 Vests earlier of this date or day before next annual meeting

Key Terms

restricted stock units, Grant, award, or other acquisition, Form 4, annual meeting of shareholders

4 terms

restricted stock units financial

"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

annual meeting of shareholders regulatory

"the business day prior to the Company's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Paul W. Graves report in his Form 4 for CRL?

Paul W. Graves reported receiving a grant of 1,438 shares of Charles River Laboratories common stock at $177.62 per share. This was a compensation-related stock award, not an open-market purchase, and increased his direct holdings to 2,384 shares.

Was the CRL Form 4 transaction a stock purchase or an award?

The Form 4 transaction for CRL reflects a stock award, not a market purchase. Graves acquired 1,438 shares through a grant classified as a “Grant, award, or other acquisition,” typical of director compensation instead of discretionary buying in the open market.

How many CRL shares does Paul W. Graves hold after this transaction?

After the reported stock award, Paul W. Graves directly holds 2,384 shares of Charles River Laboratories common stock. This total includes the newly granted 1,438 shares and represents his visible direct ownership position following the May 8, 2026 grant.

At what price was the CRL stock award to Paul W. Graves valued?

The 1,438-share award to Paul W. Graves was valued at $177.62 per share. This value is used in the Form 4 to describe the grant price for the common stock received as part of his director compensation package at Charles River Laboratories.

When do Paul W. Graves’ CRL restricted stock units vest?

The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day before Charles River Laboratories’ next annual shareholder meeting. This schedule determines when the award fully converts into unrestricted shares available to Graves.

Does the CRL Form 4 show any stock sales by Paul W. Graves?

The Form 4 shows no stock sales by Paul W. Graves. It reports only one acquisition transaction classified as a grant or award, with 1,438 shares received and total direct holdings rising to 2,384 shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Graves Paul W

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		1,438(1)	A	$177.62	2,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

	/s/ Paul Graves	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)